Collectively, our results confirm and extend the observation by Biermann et al. that the AXL-high program is not a defining feature of MBMs, while further demonstrating its dynamic regulation across the full spectrum of melanoma progression, from primary tumors to extracranial and brain metastases. This evidence concerns the gene AXL and melanoma.